Literature DB >> 7865902

Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.

M F Cheng1, S Chatterjee, N A Berger.   

Abstract

The schedule-dependent cytotoxic effects of topotecan were evaluated in tissue culture experiments with Chinese hamster V79 cells. One hour exposure to topotecan resulted in a typical phase-specific cell killing curve in which increasing concentrations kill progressively more cells and then reach a plateau when all susceptible cells are killed. In contrast, exposure for 24 h results in a steep concentration-response curve with no plateau. Other S-phase agents such as hydroxyurea or aphidicolin antagonized cytotoxicity when administered by simultaneous exposure with topotecan. Combinations of melphalan, BCNU (1,3 bis(2-chloroethyl)-1-nitrosourea), or cisplatinum with topotecan were most effective when cells were exposed to the alkylating agent or platinating agent during the first hour of a 24-h topotecan exposure. Combinations of topotecan with etoposide or adriamycin produce more cytotoxicity when topotecan is administered by prolonged exposure; however, there is no significant difference depending on whether the topoisomerase II inhibitor is added at the beginning or end of the topotecan exposure. These studies show the importance of appropriate dose scheduling to obtain optimal interaction of chemotherapeutic agents given in combination with topotecan.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865902

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  12 in total

Review 1.  Topoisomerase I interactive drugs in children with cancer.

Authors:  C F Stewart; W C Zamboni; W R Crom; A Gajjar; R L Heideman; W L Furman; W H Meyer; P J Houghton; C B Pratt
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.

Authors:  YaJuan Shao; Mei Guan; ShuChang Chen; Ning Jia; YuZhou Wang
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

3.  Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.

Authors:  M Taron; C Plasencia; A Abad; C Martin; M Guillot
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

4.  Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.

Authors:  Janelle B Perkins; Steven C Goldstein; Jana L Dawson; Jongphil Kim; Teresa L Field; James S Partyka; Karen K Fields; Beth L Maddox; Christine E Simonelli; Anthony M Neuger; Richard M Lush; Daniel M Sullivan
Journal:  Clin Cancer Res       Date:  2011-10-25       Impact factor: 12.531

Review 5.  [Topoisomerase I inhibitor with potential radiosensitizing effect].

Authors:  R Sauer; A Heuser
Journal:  Strahlenther Onkol       Date:  1997-03       Impact factor: 3.621

6.  Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma.

Authors:  C Meazza; M Casanova; E Zaffignani; R Luksch; M Podda; F Favini; S Catania; V Biassoni; C Morosi; A Ferrari
Journal:  Med Oncol       Date:  2008-08-05       Impact factor: 3.064

Review 7.  Topotecan. A review of its potential in advanced ovarian cancer.

Authors:  R N Brogden; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

8.  Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.

Authors:  Yong-Wei Zhang; Tamara L Jones; Scott E Martin; Natasha J Caplen; Yves Pommier
Journal:  J Biol Chem       Date:  2009-05-05       Impact factor: 5.157

9.  Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

Authors:  Eufemia Jacob; Kathy Scorsone; Susan M Blaney; David Z D'Argenio; Stacey L Berg
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167

10.  Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

Authors:  V M Herben; W W ten Bokkel Huinink; A C Dubbelman; I A Mandjes; Y Groot; D M van Gortel-van Zomeren; J H Beijnen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.